Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine. Hosted by Adrian Dawkes.
